systemic lupus erythematosus


Also found in: Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.

systemic lupus er·y·the·ma·to·sus

 (ĕr′ə-thē′mə-tō′sĭs)
n. Abbr. SLE
An inflammatory autoimmune disease that affects multiple organ systems, usually characterized by fatigue, fever, skin lesions, joint pain and swelling, and anemia, and often affecting the kidneys and various other organs. It is much more common in women than in men.

system′ic lu′pus er•y•the•ma•to′sus

(ˌɛr əˌθi məˈtoʊ səs, -ˌθɛm ə-)

n.
an autoimmune inflammatory disease of the connective tissues, chiefly characterized by skin eruptions, joint pain, recurrent pleurisy, and kidney disease.
[1950–55]

systemic lupus erythematosus

(SLE) A systemic (not localized) autoimmune disorder. It particularly affects the joints, skin, lungs, and kidneys.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.systemic lupus erythematosus - an inflammatory disease of connective tissue with variable features including fever and weakness and fatigability and joint pains and skin lesions on the face or neck or arms
lupus - any of several forms of ulcerative skin disease
References in periodicals archive ?
United Kingdom-based AstraZeneca has achieved its primary endpoint in the phase III Tulip two trial of new medicine anifrolumab for systemic lupus erythematosus, it is reported today.
Systemic lupus erythematosus (SLE) is a chronic, multisystemic autoimmune disease with different clinical and serological manifestations that can affect almost any organ and involvement patterns dramatically change from one patient to another.
ENPNewswire-August 30, 2019--AstraZeneca - Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus
M2 PRESSWIRE-August 29, 2019-: Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease with often nonspecific symptoms that can lead to a delay in diagnosis.
SLE (systemic lupus erythematosus) is a chronic, incurable, autoimmune disease associated with a range of symptoms including painful or swollen joints, extreme fatigue, unexplained fever, skin rashes and organ damage.
KEYWORDS: Mean Pulmonary Arterial Pressure (MPAP), Pulmonary Arterial Hypertension (PAH), Pulmonary Artery Systolic Pressure (PASP), Systemic Lupus Erythematosus (SLE).
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease under genetic control.
I read with interest the article by Siti et al, (1) on pediatric systemic lupus erythematosus, retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score (SLEDAI).
Renal involvement is a major cause of morbidity and hospital admissions in patients with systemic lupus erythematosus (SLE) and occurs in up to 60% of lupus patients during course of disease.1The SLE patients with lupus nephritis (LN) who has APL antibodies have even poorer prognosis.
Infection is a major source of morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE).

Full browser ?